A First-in-human Research Study on How NNC0721-8060 Works in People Living With Overweight or Obesity

Recruiting · NCT07767175 · Interventional (participants receive a specific treatment)

Interventions studied

NNC0721-8060PlaceboSemaglutide

The purpose of the study is to find out if NNC0721-8060 is safe and how it works in people living with overweight or obesity.

Age range

18 Years to 55 Years

Sex

All (male and female)

Healthy volunteers

Yes - healthy volunteers may be accepted

Phase

Phase 1

Study type

Interventional (participants receive a specific treatment)

Male or female (sex at birth).
Age 18-55 years (both inclusive) at the time of signing informed consent.
Body Mass Index (BMI) 27.0-34.9 kilograms per square metre (kg/m\^2) (both inclusive) at screening, with overweight due to excess adipose tissue as judged by the investigator.
Considered eligible based on medical history, physical examination, vital signs, electrocardiogram and clinical laboratory tests at screening, as judged by the investigator.

Known or suspected hypersensitivity to study intervention(s) or related products.
Previous randomisation in this study.
History of allergies (with the exception of seasonal allergies) or history of anaphylactic reactions.
Female who is pregnant, breastfeeding, intends to become pregnant, or is of childbearing potential and not using adequate contraception.
Current participation (signed informed consent) in any other interventional clinical study.
Exposure to an investigational medicinal product within 30 days or five half-lives of that product (whichever is longer) before screening.
Any disorder, unwillingness or inability which, in the investigator's opinion, might jeopardise participant safety or compliance with the protocol.
Glycated haemoglobin (HbA1c) greater than or equal to (≥) 6.5 percentage (%) (48 millimoles per mole \[mmol/mol\]) at screening.

2 locations listed across 2 US states.